Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Mirum Pharmaceuticals, Inc. MIRM
$26.17
-$0.05 (-0.19%)
На 18:01, 12 мая 2023
+133.09%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1004419838.00000000
-
week52high
30.55
-
week52low
17.32
-
Revenue
77062000
-
P/E TTM
-7
-
Beta
1.31570500
-
EPS
-4.04000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 24 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 23 мая 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 06 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 26 апр 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 11 мар 2022 г. |
| Citigroup | Buy | 01 сент 2022 г. | |
| Raymond James | Strong Buy | Strong Buy | 25 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 25 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 14 ноя 2022 г. |
| Citigroup | Buy | Buy | 10 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 янв 2023 г. |
| Raymond James | Strong Buy | Strong Buy | 10 янв 2023 г. |
| SVB Leerink | Outperform | Outperform | 14 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Longpre Lara | A | 38500 | 38500 | 31 янв 2023 г. |
| Longpre Lara | A | 106159 | 9625 | 31 янв 2023 г. |
| Peetz Christopher | A | 200000 | 200000 | 31 янв 2023 г. |
| Peetz Christopher | A | 119576 | 50000 | 31 янв 2023 г. |
| Radovich Peter | A | 57750 | 57750 | 31 янв 2023 г. |
| Radovich Peter | A | 38132 | 14440 | 31 янв 2023 г. |
| Vig Pamela | A | 38500 | 38500 | 31 янв 2023 г. |
| Vig Pamela | A | 31527 | 9625 | 31 янв 2023 г. |
| Cardon Lon | A | 34000 | 34000 | 19 дек 2022 г. |
| O'Donnell Niall | D | 1621118 | 93770 | 15 ноя 2022 г. |
Новостная лента
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2023 Earnings Call Transcript
Seeking Alpha
07 мая 2023 г. в 07:42
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q1 2023 Earnings Conference Call May 6, 2023 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President & Chief Executive Officer Peter Radovich - Chief Operating Officer Pamela Vig - Head of R&D Conference Call Participants Mani Foroohar - SVB Securities Ryan Deschner - Raymond James Operator Operator Ladies and gentlemen, welcome to the Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Profile Business Update. My name is Glenn, and I will be the operator for today's call.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 19:44
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $1.17 per share a year ago.
Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up
Zacks Investment Research
15 мар 2023 г. в 10:42
Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Call Transcript
Seeking Alpha
08 мар 2023 г. в 22:40
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Corporate Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President and Chief Executive Officer Ian Clements - Chief Financial Officer Peter Radovich - Chief Operating Officer Pamela Vig - Head of R&D Conference Call Participants Jessica Fye - JPMorgan Mani Foroohar - SVB Securities Josh Schimmer - Evercore Ryan Deschner - Raymond James David Lebowitz - Citi Brian Skorney - Baird Ed Arce - H.C. Wainwright Yasmeen Rahimi - Piper Sandler Operator Good afternoon.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
08 мар 2023 г. в 21:49
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -1.02% and 11.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?